Opthea Limited (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea Limited (ASX: OPT)
Latest News
Share Gainers
Why Lotus Resources, Opthea, Qoria, and Sims shares are charging higher today
Share Gainers
Why ARB, Guzman Y Gomez, Opthea, and Yancoal shares are storming higher
Healthcare Shares
2 promising small-cap ASX healthcare stocks to buy now
Speculative
'Blockbuster opportunity': This speculative ASX stock could rise 70%
Share Gainers
Why Atturra, Bravura, Core Lithium, and Opthea shares are racing higher today
Share Fallers
Why Core Lithium, Deterra Royalties, Northern Star, and Opthea shares are dropping
Share Fallers
Why A2 Milk, Lindsay Australia, Meridian Energy, and Opthea shares are falling today
Share Fallers
Why Opthea, Pantoro, Premier Investments, and Wildcat shares are falling
Share Fallers
Why APA Group, Cettire, Deep Yellow, and Opthea shares are falling today
Share Gainers
Why Arcadium Lithium, Boart Longyear, Opthea, and Orecorp shares are rising today
Healthcare Shares
Why did the Opthea share price dive 9% on Monday?
Share Fallers
Why Beach, Bendigo and Adelaide Bank, Opthea, and Paradigm shares are sinking
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea Limited
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
